Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Kalytera Therapeutics Inc. (V:KLY)

Business Focus: Biotechnology & Medical Research

Dec 02, 2019 08:30 am ET
Kalytera Reports Third Quarter 2019 Financial Results
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results for the third quarter of 2019. (All dollars U.S. unless otherwise noted.)  Third Quarter Financial ResultsIn Q3...
Nov 22, 2019 08:30 am ET
Published Studies Provide Further Support For Kalytera’s Program Evaluating CBD in GVHD
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that research reported in two peer-reviewed articles published in Blood provide further evidence supporting the activity of cannabidiol...
Oct 30, 2019 10:10 pm ET
Kalytera Announces Closing of Final Tranche of Private Placement of Common Shares and Common Share Purchase Warrants and Amendments to Secured Convertible Debenture Units
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce that it has closed an additional and final tranche of its private placement, for 2,811,111 common shares of the Company and...
Oct 21, 2019 11:07 pm ET
Kalytera Provides Update on Private Placement of Common Shares and Common Share Purchase Warrants
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce that it has closed an additional tranche of its private placement, for 1,974,445 common shares of the Company and 1,974,445 common...
Oct 17, 2019 08:30 am ET
Kalytera Terminates Plan to Acquire CBD Extraction Facility
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") has announced that, due to a decline in the market price for CBD isolate, it has decided not to proceed with its previously announced plan to acquire a...
Oct 02, 2019 08:30 am ET
Kalytera Announces Notice of Allowance of EU Patent for Prevention and Treatment of Graft Versus Host Disease
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") is pleased to announce that the European Patent Office has issued a Notice of Allowance for EU Patent Application Number 14791611.8 covering the use of...
Sep 16, 2019 01:06 pm ET
Kalytera Announces Closing of First Tranche of Private Placement of Common Shares and Common Share Purchase Warrants
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce the closing of the first tranche of its private placement, for 10,946,423 common shares of the Company and 10,946,423 common share...
Sep 11, 2019 10:50 am ET
Kalytera Announces Update to Private Placement
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it is updating the terms of its private placement previously announced on August 21, 2019 (the “Private Placement”).  The Company...
Sep 09, 2019 09:48 pm ET
Kalytera Announces Interest Payment in Shares
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has elected to make an interest payment under the C$787,500 principal amount secured convertible debenture issued in a private...
Aug 29, 2019 11:25 pm ET
Kalytera Reports Second Quarter 2019 Financial Results
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results for the second quarter of 2019. (All dollars U.S. unless otherwise noted.) “Kalytera made important progress in its...
Aug 21, 2019 08:30 am ET
Kalytera Announces Management-Led Private Placement of Up To $1.5 Million of Common Shares and Common Share Purchase Warrants
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it intends to raise up to approximately CDN $1.5 million (USD $1.13 million) in a private placement (the “Private Placement”) of...
Aug 19, 2019 08:00 am ET
Kalytera to Conclude Phase 2 Clinical Study and Initiate Phase 3 Study
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that interim results from the Company’s Phase 2 clinical study evaluating cannabidiol (“CBD”) for the prevention of acute graft versus...
Jul 29, 2019 02:52 pm ET
Kalytera Announces Results of Shareholder Meeting Votes
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that shareholder votes on the election of directors, the approval of the Company’s auditors and the renewal of its Stock Option Plan were...
Jul 26, 2019 06:01 pm ET
Kalytera Will Not Proceed with Vote on Potential Share Consolidation
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that after consultations with major shareholders, the board of directors of the Company has decided not to proceed at this time with the...
Jul 16, 2019 08:30 am ET
Kalytera Announces Completion of Food Effect and QTc Study
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has completed Study KAL-07, the Food Effect and QTc Study, that is part of the Company’s product development program evaluating...
Jul 05, 2019 05:07 pm ET
Kalytera to Hold Annual and Special Meeting on July 29, 2019
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that it is holding its annual and special meeting of shareholders on July 29, 2019 (together with any adjournment or postponement thereof,...
Jun 27, 2019 08:30 am ET
Kalytera to Acquire CBD Extraction Business
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that it has signed a Letter of Intent (“LOI”) to acquire a majority interest in Oregon 01, LLC (doing business as “Clean Bi Design”),...
Jun 25, 2019 09:54 am ET
Kalytera Provides Update on GVHD Program
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today provided an update on its lead product development program evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease...
Jun 21, 2019 05:47 pm ET
Kalytera Announces Grant of Stock Options to Directors
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has granted stock options on June 19, 2019 to the directors of the Company.  The stock options have an exercise price of $0.05...
Jun 21, 2019 10:00 am ET
Kalytera Announces Changes to Board of Directors
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced changes to the Company’s Board of Directors (the "Board"). Mr. Robin “Rob” Hutchison has joined the Board to fill the vacancy created by...
Jun 18, 2019 08:30 am ET
Kalytera Announces Additional Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has invented a novel first-in-class cannabinoid molecule, designated KAL-1816, that strongly and selectively binds with and...
May 31, 2019 08:30 am ET
Kalytera Reports First Quarter 2019 Financial Results
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results for the first quarter of 2019. (All dollars U.S. unless otherwise noted.) “Since the beginning of the year, we have made...
May 29, 2019 08:30 am ET
Kalytera Announces Submission of Patent Application to the U.S. Patent and Trademark Office
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (“USPTO”) covering Kalytera’s novel...
May 28, 2019 08:30 am ET
Kalytera Announces Data Further Elucidating CBD’s Mechanisms of Action in Prevention of GVHD
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced new laboratory findings demonstrating that cannabidiol (“CBD”) acts through a distinct biological pathway to restore epithelial cell tight...
May 14, 2019 10:33 am ET
Kalytera Therapeutics, Inc. Announces Second Closing of Public Offering
Kalytera Therapeutics, Inc. (TSX Venture: KLY) (OTCQB:KALTF) (the “Company” or “Kalytera”) is pleased to announce the second closing of its previously announced public offering (the “Offering”) of units of the Company (“Units”) for aggregate gross...
May 01, 2019 04:10 pm ET
Kalytera Reports 2018 Financial Results
Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results for the year ended December 31 2018. (All dollars U.S. unless otherwise noted.) Investors should note that the Company’s...
Apr 26, 2019 10:16 am ET
Kalytera Therapeutics, Inc. Announces Closing of Public Offering
Kalytera Therapeutics, Inc. (TSX Venture: KLY) (OTCQB:KALTF) (the “Company” or “Kalytera”) is pleased to announce the closing of its previously announced public offering (the “Offering”) of units of the Company (“Units”) for aggregate gross...